×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SCNX – scienture holdings, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SCNX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/14
01:32 am
scnx
Scienture (SCNX) was upgraded by Wall Street Zen to "hold".
Low
Report
Scienture (SCNX) was upgraded by Wall Street Zen to "hold".
3/11
08:14 am
scnx
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions [Yahoo! Finance]
Medium
Report
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions [Yahoo! Finance]
3/11
08:05 am
scnx
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
High
Report
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
2/24
12:52 pm
scnx
Scienture (NASDAQ:SCNX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.
Low
Report
Scienture (NASDAQ:SCNX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.
2/3
08:23 am
scnx
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium [Yahoo! Finance]
Medium
Report
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium [Yahoo! Finance]
2/3
08:05 am
scnx
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Low
Report
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
1/25
03:05 am
scnx
Scienture (NASDAQ:SCNX) was downgraded by analysts at Wall Street Zen
Medium
Report
Scienture (NASDAQ:SCNX) was downgraded by analysts at Wall Street Zen
1/14
08:05 am
scnx
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
Medium
Report
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
3/12
09:33 pm
scnx
Form 4 Scienture Holdings, Inc. For: Sep 19 Filed by: Shankar Hariharan
Medium
Report
Form 4 Scienture Holdings, Inc. For: Sep 19 Filed by: Shankar Hariharan
3/12
09:32 pm
scnx
Form 4 Scienture Holdings, Inc. For: Sep 19 Filed by: Narasimhan Mani
Medium
Report
Form 4 Scienture Holdings, Inc. For: Sep 19 Filed by: Narasimhan Mani
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: